Patient-controlled Analgesic Pumps Market is segmented By Type(Electronic & Mechanical), By Application(Hospitals, Clinics, Ambulatory Surgical Centers, Homecare settings, and Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Patient-controlled Analgesic Pumps Market Overview
The Patient-controlled Analgesic Pumps Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Patient-controlled analgesic pumps are devices used to deliver pain medication to patients on demand. The market is driven by the growing need for effective pain management solutions and the increasing prevalence of chronic pain conditions. In the Asia Pacific region, the Patient-controlled Analgesic Pumps Market is witnessing significant growth. Key players in the market include Company G, Company H, Company I, and other prominent players.
Patient-controlled Analgesic Pumps Market Scope and Summary
|
Metrics |
Details |
|
Market CAGR |
5.6% |
|
Segments Covered |
By Pet Type, By Application, By End User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For more insights - Download the Sample
Patient-controlled Analgesic Pumps Market Dynamics and Trends
The patient-controlled analgesia pump market is driven by the increase in the prevalence of chronic disorders around the globe. And the incorporation of the newest technology in PCA pumps will drive the market over the forecast period. Disadvantages may include its underdose or overdose.
Increase in the prevalence of chronic disorders
About 40 million Americans are limited in their usual activities due to one or more chronic health conditions. The growing number of people suffering from chronic pain will enhance the overall market growth. This chronic pain and disorders require analgesic pumps for timely pain relief, leading to the demand for patient-controlled analgesia pumps.
Advancement in technology to enhance PCA pumps
PCA pump is a computerized pump that contains a syringe of medication, which delivers a small amount of medication in a constant flow. Incorporating the newest technology in PCA pumps helps in faster pain recovery and leads to increased patient preference, thereby accelerating market growth. This aids patients in controlling pain and allows them to feel comfortable while minimizing the need for on-site support from hospital members.
Problems associated with the use of PCA pumps
Possibility of under-dose or overdose of medication, nurse assistance is required for children aged less than 5 years and difficult to use in critically ill patients. Lack of awareness about using a Patient-controlled analgesia pump.
In addition to the complexity of the infusion pump, IV PCA safety concerns extend to the side effects associated with the drugs themselves. Published data on IV PCA side effect profiles show that approximately 50% of patients experience sedation. Oxygen desaturation has been shown to occur in approximately 10% of patients.15,16 Morphine, still utilized in the majority of post-operative IV PCA cases, has active metabolites, which are eliminated by the kidney and can lead to unanticipated pharmacokinetic-pharmacodynamic effects, such as prolonged duration of action and untoward side effects in patients with decreased renal function.
COVID-19 Impact on Patient-controlled Analgesic Pumps Market Growth
With an increase in COVID-19 cases and restrictions, the growing trend of home healthcare during the COVID-19 pandemic is expected to increase the market growth in the coming years. However, due to restricted number of surgeries due to COVID-19 caused a decline in the market.
Patient-controlled Analgesic Pumps Market Segment and Shares
By Type, the Patient-controlled Analgesic Pumps Market is divided into electronic and mechanical.
The electronic segment accounted for the largest share of the market
In a hospital setting, a PCA refers to an electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button. PCA can be used for both acute and chronic pain patients. It is commonly used for post-operative pain management and end-stage cancer patients. Electronic PCA pumps are suitable for a large population base, as they can be regulated based on patients' needs. Hence, this segment will grow in the forecast period.
By application, the Patient-controlled Analgesic Pumps Market is segmented into Diabetes, Oncology, Gastroenterology, Hematology, and Others
The oncology segment held the largest share of the market
PCA pumps control cancer pain by self-administration of intravenous opioids with the use of a programmable pump. Patient-controlled analgesia pumps are used by patients at home suffering from moderate to severe pain from cancer. Thus the increasing number of hospitals, ambulatory surgical centers, and specialty centers in developed and developing countries providing pain management solutions among cancer patients is expected to boost the market growth.
Based on End-user, the Patient-controlled Analgesic Pumps Market is divided into ambulatory surgical centers, hospitals, home care settings, and others.
The hospital segment dominated the market
Patient-controlled analgesia Application is most commonly used in hospital settings. The availability of the most advanced Patient-controlled analgesia pumps in hospitals and the most demand in this segment is anticipated to fuel the growth of its market.
North America dominated the market for Patient-controlled Analgesic Pumps
Increasing cases of diabetes, cancer, accidental injuries, and other diseases related to pain management are expected to secure the growth of the patient-controlled analgesia pump market.
Nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents. Patient-controlled analgesia pumps are increasingly being preferred in the management of type-1 diabetes for pain control.
The Asia Pacific is expected to see a rise in the market over the forecast period. The increasing incidence of chronic disorders along with rising awareness about new technologies.
Patient-controlled Analgesic Pumps Market Geographical Analysis
The patient-controlled analgesia (PCA) pump is a computerized machine that gives you medicine for pain when you press a button. In most cases, PCA pumps supply opioid pain-controlling medicines such as morphine, fentanyl, and hydromorphone. The pump is attached to a thin, flexible tube (intravenous or IV line) placed in your vein. This medicine is usually delivered only when you press the button (bolus), but the doctor adds a continuous rate if needed (basal rate).
People who use the pumps have better pain control and satisfaction compared to nurse-administered boluses. They experience less anxiety and can relax as they feel more in control of their pain.
Patient-controlled Analgesic Pumps Companies and Competitive Landscape
The patient-controlled analgesia pump market is moderately competitive and consists of several major players. A few of the major players currently dominating the market are Smiths Group Plc, Becton, Dickinson and Company, Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Baxter International Inc., ICU Medical, Abbott Laboratories, Avante Health Solutions, Fresenius Kabi and Ace Medical
Baxter International Inc.
Overview: Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter International Inc. designs the flexible Ipump system to help each patient become ambulatory as quickly as possible. Pain management can be tailored to both a patient's individual needs and clinical priorities through a variety of convenient options.
Product Portfolio: The Company's portfolio is comprised of products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions
